Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | STAMBP | O95630 | 1/20 | 0.42 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 8/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150699 | 0.84 | MGAM (0.46) | PSMD14LMNA | |
| SCHEMBL6226860 | 0.82 | KDM4E (0.41) | HPGDSLMNA | |
| SCHEMBL22749174 | 0.74 | HPGDS (0.45) | HPGDSPSMD14STAMBPCOPS5NNMT | |
| SCHEMBL3412853 | 0.72 | ROCK1 (0.34) | — | |
| SCHEMBL160863 | 0.71 | NAMPT (0.44) | HPGDSPSMD14STAMBPCOPS5NNMT | |
| SCHEMBL29511927 | 0.71 | NAMPT (0.44) | HPGDSPSMD14STAMBPCOPS5NNMT | |
| SCHEMBL16517720 | 0.71 | HPGDS (0.50) | HPGDSPSMD14STAMBPCOPS5NNMT | |
| SCHEMBL28114582 | 0.71 | PSMD14 (0.47) | HPGDSPSMD14STAMBPCOPS5NNMT | |
| SCHEMBL14994140 | 0.70 | LCK (0.46) | CHEK2 | |
| SCHEMBL29755236 | 0.70 | PSMD14 (0.46) | HPGDSPSMD14STAMBPCOPS5NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267566-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2022140415-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | claimed |
| EP-3994138-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRalpha) MODULATORS | Lead Pharma Holding B.V. (NL) | 2022-05-11 | — | — | EP | claimed |
| EP-3856735-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | New York University (US) | 2021-08-04 | — | — | EP | claimed |
| WO-2021001453-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2021-01-07 | — | — | WO | claimed |
| WO-2020073031-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | NEW YORK UNIVERSITY (US) | 2020-04-09 | — | — | WO | claimed |
| WO-2018078005-A1 | AMIDO-SUBSTITUTED AZASPIRO DERIVATIVES AS TANKYRASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2009095752-A1 | FUSED PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-08-06 | — | — | WO | claimed |
| JP-2007514704-A | — | — | 2007-06-07 | — | — | JP | claimed |
| EP-1737857-A1 | PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | claimed |
| EP-1735315-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | claimed |
| WO-2005090353-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| EP-1539753-A2 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | claimed |
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| US-3966746-A | ATARACTIC, ANALGESIC, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3840546-A | AMINO DERIVATIVES OF PYRAZOLOPYRIDINE CARBOXAMIDES | SQUIBB & SONS INC | 1974-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | HPGDS 2200/4885PSMD14 670/4885STAMBP 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.